Law360, New York (May 15, 2009, 12:00 AM ET) -- The U.S. Patent and Trademark Office has ruled on two of four StemCells Inc. patents-at-issue with rival biotech firm Neuralstem Inc., paving the way for infringement litigation between the companies to move forward.
Palo Alto, Calif.-based StemCells said Friday that the patent office had issued notices of intent to issue ex parte re-examination certifications for U.S. Patent Numbers 6,294,346 and 7,101,709, which relate to the use of human stem cells for screening drugs and for screening biological agents, respectively.
The patents are among six patents StemCells...
USPTO Rules On Stem Cell Patents In Biotech Battle
To view the full article, take a free trial now.
